Stockscreener 앱 받기
3.37
4.26%
-0.15
시간 외 거래:
3.37
전일 마감가:
$3.52
열려 있는:
$3.52
하루 거래량:
13.37M
Relative Volume:
0.87
시가총액:
$1.79B
수익:
$74.68M
순이익/손실:
$-644.76M
주가수익비율:
-2.2726
EPS:
-1.4829
순현금흐름:
$-380.44M
1주 성능:
-1.17%
1개월 성능:
+8.36%
6개월 성능:
-32.06%
1년 성능:
-29.13%
1일 변동 폭
$3.32
$3.5579
1주일 범위
$3.20
$3.59
52주 변동 폭
$2.80
$7.18
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.37 | 1.87B | 74.68M | -644.76M | -380.44M | -1.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Recursion earnings in focus as AI drug platform faces revenue test - Investing.com
Blake Borgeson sells 200,000 Class A shares (RXRX) under Rule 144 - Stock Titan
Recursion Pharmaceuticals Stock Short Interest Rises to 35.49% - Quiver Quantitative
Recursion Pharmaceuticals Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView
News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat - Sahm
Is It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings? - Yahoo Finance
Does Recursion’s 2026 Update And Board Shift Reframe Its AI Drug Discovery Ambitions For RXRX? - Sahm
What Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny Stock - Insider Monkey
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Investor Sentiment Splits On Future Prospects - Sahm
Recursion Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Recursion Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings - TechStock²
Recursion Pharmaceuticals : 2026 Proxy Statement - marketscreener.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at JPMorgan Chase & Co. - MarketBeat
Recursion Pharmaceuticals Announces Planned Board Leadership Transition - TipRanks
Recursion Pharmaceuticals | DEFA14A: Others - Moomoo
[ARS] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Recursion (RXRX) outlines 2026 virtual meeting, board elections and pay votes - Stock Titan
Recursion founder exits board in June but stays on as adviser - Stock Titan
Recursion Pharmaceuticals | 8-K: Current report - Moomoo
Founder Chris Gibson to exit Recursion Pharmaceuticals (NASDAQ: RXRX) board - Stock Titan
Recursion Announces Board Transition - marketscreener.com
MSN Money - MSN
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RXRX stock soars pre-market on Q4 beat, Recursion CEO says company has ‘reached an inflection point’ - MSN
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 - marketscreener.com
Recursion opens May 6 earnings call to public questions online - Stock Titan
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN
Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' (NASDAQ:RXRX) - Seeking Alpha
Recursion names Vicki Goodman as CMO - MSN
Recursion Pharmaceuticals May Be Losing Ground To Its Peers (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals Projects Massive Growth Amid Clinical Success - HarianBasis.co
Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities - Insider Monkey
Recursion names Najat Khan CEO, succeeding co-founder Chris Gibson; stock down - MSN
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market - MSN
Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast - Yahoo Finance
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
10 Most Shorted Penny Stocks to Buy - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention - Yahoo Finance
Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com India
Recursion Pharmaceuticals director Gibson sells $144,400 in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan
ETFs Investing in Recursion Pharmaceuticals, Inc. Class A Stocks - TradingView
AI-Driven Target Discovery Breakthrough Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX) - simplywall.st
Christopher Gibson sells Class A shares (NASDAQ: RXRX) in four filings - Stock Titan
Recursion Pharmaceuticals Uses AI to Accelerate Drug Development - HarianBasis.co
Recursion Pharmaceuticals Inc (RXRX): Is AI Strategy Working? - Insider Monkey
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):